Detalhe da pesquisa
1.
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
JAMA
; 331(17): 1460-1470, 2024 05 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38581198
2.
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Lancet Oncol
; 24(6): 669-681, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37187202
3.
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
J Urol
; 209(6): 1112-1119, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36951811
4.
Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit.
Lancet Oncol
; 22(5): e207-e215, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33676600
5.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
J Urol
; 205(1): 22-29, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32960678
6.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
J Urol
; 205(1): 14-21, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32960679
7.
Radiation treatment in prostate cancer: covering the waterfront.
BJU Int
; 128(4): 398-407, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34273237
8.
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
N Engl J Med
; 376(5): 417-428, 2017 02 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28146658
9.
Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
J Urol
; 201(4): 721-727, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30664083
10.
Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
J Urol
; 199(2): 407-415, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28870862
11.
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
J Urol
; 198(3): 552-559, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28456635
12.
Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams.
Acta Oncol
; 56(4): 575-581, 2017 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28075206
13.
Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer.
J Appl Clin Med Phys
; 18(3): 37-43, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28407345
14.
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.
Br J Cancer
; 115(1): 90-4, 2016 Jun 28.
Artigo
Inglês
| MEDLINE | ID: mdl-27253172
15.
Radiation oncology authors and reviewers prefer double-blind peer review.
Proc Natl Acad Sci U S A
; 115(9): E1940, 2018 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-29434045
16.
Can proton therapy be considered a standard of care in oncology? Lessons from the United States.
Br J Cancer
; 120(8): 775-776, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30911089
17.
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy.
BJU Int
; 114(4): 511-6, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24112602
18.
Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay.
BJU Int
; 124(1): 35-39, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30680874
19.
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Lancet Oncol
; 14(9): 863-72, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23823157
20.
A Multi-Institutional Survey of Radiation Oncology Professionals' Knowledge, Attitudes, and Practice Behaviors Toward Sexual and Gender Minority Patients With Cancer.
Adv Radiat Oncol
; 9(5): 101461, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38550362